Kathryn Haviland
Chief Executive Officer at BLUEPRINT MEDICINES CORPORATION
Net worth: 15 M $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Gould | M | 69 | - | |
| Alexis Borisy | M | 52 | 16 years | |
| Jeffrey Albers | M | 52 | 10 years | |
| Alexander Sapir | M | 57 | 1 years | |
| Tracey McCain | F | 56 | 8 years | |
| Claire Mazumdar | M | - |
Bicara Therapeutics, Inc.
 Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | - |
| Christina Rossi | F | 48 |
Harvard Business School
| 9 years |
| Nicholas B. Lydon | M | 67 | 16 years | |
| Christine Utter | F | 46 | 14 years | |
| Habib Dable | M | 54 | 2 years | |
| Anthony Boral | M | 56 | 9 years | |
| Michael Landsittel | M | 52 | 10 years | |
| John Tsai | M | 57 | 1 years | |
| James Geraghty | M | 69 | 8 years | |
| Becker Hewes | M | 58 | 4 years | |
| Mel Hayes | M | 54 | 3 years | |
| Sonja Banks | F | 55 | 3 years | |
| Katina Dorton | F | 66 | 4 years | |
| Lynn Seely | M | 65 | 8 years | |
| Leslie Leinwand | M | - | - | |
| James Collins | M | 58 | 7 years | |
| Alan Musso | M | 62 | 1 years | |
| Lonnel Coats | M | 58 | 8 years | |
| Cecilia Gonzalo | F | 49 |
Harvard Business School Health Industry Alumni Association
| - |
| R. Alan B. Ezekowitz | M | 70 | 8 years | |
| Mark Goldberg | M | 69 | 9 years | |
| Iain Fraser | M | - | 1 years | |
| Daniella Beckman | F | 45 | 3 years | |
| Jeffrey W. Jacobs | M | 61 | 2 years | |
| Todd Davis | M | 63 |
Harvard Business School Health Industry Alumni Association
| - |
| Kristina Storey | F | - | 2 years | |
| Dee Smith | M | - | - | |
| Paul Bruno | M | - | 5 years | |
| Susan Alesina | F | 61 |
Harvard Business School Health Industry Alumni Association
| - |
| Janet Loesberg | M | 61 | 4 years | |
| Gregory Tourangeau | M | - | 2 years | |
| Fouad Namouni | M | 55 | 4 years | |
| Kiran Mazumdar-Shaw | F | 71 |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | - |
| Mani Sundararajan | M | - | 3 years | |
| Steve Hodi | M | - |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | - |
| Jeremy Levin | M | - |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | - |
| Nils Lonberg | M | - |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | - |
| Emily Levy | F | - |
Harvard Business School Health Industry Alumni Association
| - |
| Philina Lee | M | 47 | 10 years | |
| Kim Hazen | F | - | 7 years | |
| Dallan Murray | M | - | 11 years | |
| Percy Carter | M | 53 | 3 years | |
| Lauren Barnes | F | 50 | - | |
| Curtis Oltmans | M | 60 | 4 years | |
| Ariel Hurley | F | 50 | 10 years | |
| Andrew Law | M | - | - | |
| Jesús Martin-Garcia | M | 62 |
Harvard Business School Health Industry Alumni Association
| - |
| Scott Robertson | M | - |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | 1 years |
| Christopher Murray | M | 61 | 7 years | |
| Vijay Kumar Kuchroo | M | 68 |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | - |
| David Scharfstein | M | 63 |
Harvard Business School
| 21 years |
| Nitin Thakor | M | - |
Harvard Business School Health Industry Alumni Association
| - |
| Bumpus Durso | F | 54 | 9 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Vin Milano Milano | M | 60 |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | - |
| Bryan Stuart | M | 47 | 5 years | |
| Michael Jacobsen | M | 65 | 2 years | |
| John J. Kirby | M | 52 |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | - |
| Mark Levin | M | 73 | - | |
| Jill Conwell | F | - |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | - |
| Robert Karr | M | 75 |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | 10 years |
| Jielun Zhu | M | 48 |
Wesleyan University
Harvard Business School
| 7 years |
| Nancy M. Wyant | F | - |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | 3 years |
| Abdul-Wahab Umari | M | - |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | 2 years |
| Kristin Hodous | F | - | 9 years | |
| Esther Rajavelu | F | 46 | 1 years | |
| Benjamin Perl | M | - |
Wesleyan University
Harvard Business School
| 7 years |
| Aaron Michel | M | - |
Harvard Business School
| 3 years |
| Jessica Goldin | F | - |
Wesleyan University
Harvard Business School
| 7 years |
| Anu Bhattacharyya | F | - | - | |
| Mark Joseph Casey | M | 60 |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | 3 years |
| Theresa Natalicchio | F | - | - | |
| Christi Waarich | F | - | - | |
| Christopher Moxham | M | 56 | - | |
| Peter Thomson | M | 56 | 4 years | |
| Christine Bellon | M | 59 | - | |
| Alex Sloane | M | - |
Harvard Business School
| 10 years |
| Naomi Aoki | F | - | - | |
| Robert A. Doody | M | - |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | - |
| Jesse Feldman | M | 47 |
Harvard Business School
Wesleyan University
| 7 years |
| C. Hartley | M | 81 |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | 17 years |
| TY Howton | M | 52 | 8 years | |
| Malcolm MacCoss | M | 76 |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | 5 years |
| Hyung-Soo Kim | M | - |
Wesleyan University
| 5 years |
| Ali Khanbhai | M | 49 |
Harvard Business School
| 2 years |
| mark ellis | M | - |
Harvard Business School
| 2 years |
| Nicholas Chan | M | - |
Harvard Business School
| 2 years |
| labi williams | M | - |
Harvard Business School
| 2 years |
| Teo Vujcic | M | - |
Harvard Business School
| 2 years |
| Radhika Dilip Piramal | F | 46 |
Harvard Business School
| 2 years |
| Tomas Ackerman | M | 44 |
Harvard Business School
| 2 years |
| Thomas Carella | M | 49 |
Harvard Business School
| 2 years |
| Robert Go | M | - |
Harvard Business School
| 2 years |
| M. Phillips | M | - |
Harvard Business School
| 2 years |
| Hank Midgley | M | - |
Harvard Business School
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 99 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Kathryn Haviland
- Personal Network